White Paper
How Radiofrequency Ablation is Transforming Benign Thyroid Nodule Treatment
A New Era in Thyroid Management
Radiofrequency ablation (RFA) represents a paradigm shift in the management of benign thyroid nodules, a common clinical problem with an estimated prevalence of up to 68% in the general population.1 In recent years, RFA has gained significant traction as a highly effective, minimally invasive treatment modality with multiple benefits over surgery.2
This white paper explores how RFA is transforming thyroid care, improving patient outcomes, and offering new growth opportunities for clinical practices.
Download the White Paper
RFA vs. Surgery
Discover how RFA outperforms traditional thyroid surgery in safety, efficacy, and patient satisfaction:
Lower Complication Rates
RFA has demonstrated a significantly lower rate of complications and postoperative pain than surgery.3,4
Preserved Thyroid Function
RFA reduces nodule size and improves related compressive and cosmetic symptoms, while preserving healthy thyroid tissue and avoiding hormone replacement therapy, in most cases.3,4
Faster Recovery
Patients typically return to normal activities within 1-2 days, compared to weeks after surgery.5,6
How Clinicians are Succeeding with RFA
Learn how adopting RFA can set your practice apart and enhance patient care:
- Expanded Treatment Options: RFA provides an effective alternative for patients who are poor surgical candidates or prefer a minimally invasive approach.4
- High Patient Satisfaction: Compared with surgery, RFA is associated with superior patient satisfaction and health-related quality of life.4
- Reimbursement Considerations: In the United States, CPT codes 60660 and +60661 are exclusive to RFA of thyroid nodules, supporting accessibility and reimbursement opportunities.7
Take the Lead in Thyroid Nodule Treatment
RFA is revolutionizing thyroid nodule management, and the CRF Thyroid RFA System by Cambridge Interventional is at the forefront of this innovation. By embracing this technology, clinicians can deliver superior care, improve patient outcomes, and expand their practice offerings.
Don’t miss out — download the white paper now to learn how you can integrate RFA into your practice and elevate your patient care.
- Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS. The Diagnosis and Management of Thyroid Nodules: A Review. JAMA. 2018 Mar 6;319(9):914-924. doi: 10.1001/jama.2018.0898.
- Sinclair CF, Baek JH, Hands KE, Hodak SP, Huber TC, Hussain I, Lang BH, Noel JE, Papaleontiou M, Patel KN, Russ G, Russell J, Spiezia S, Kuo JH. General Principles for the Safe Performance, Training, and Adoption of Ablation Techniques for Benign Thyroid Nodules: An American Thyroid Association Statement. Thyroid. 2023 Oct;33(10):1150-1170. doi: 10.1089/thy.2023.0281.
- Che Y, Jin S, Shi C, et al. Treatment of benign thyroid nodules: comparison of surgery with radiofrequency ablation. AJNR Am J Neuroradiol. 2015;36(7):1321- 1325.
- Tufano RP, Pace-Asciak P, Russell JO, Suárez C, Randolph GW, López F, Shaha AR, Mäkitie A, Rodrigo JP, Kowalski LP, Zafereo M, Angelos P, Ferlito A. Update of Radiofrequency Ablation for Treating Benign and Malignant Thyroid Nodules. The Future Is Now. Front Endocrinol (Lausanne). 2021 Jun 24;12:698689. doi: 10.3389/fendo.2021.698689.
- Stanford Medicine Health Care. Radiofrequency Ablation for Thyroid Nodules. https://stanfordhealthcare.org/medical-treatments/r/radiofrequency-ablation-thyroid-nodules.html Accessed 18 Feb 2025.
- Cleveland Clinic. Thyroidectomy. https://my.clevelandclinic.org/health/treatments/7016-thyroidectomy Accessed 08 Jan 2025.
- Department of Health and Human Services. “Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments.” Federal Register vol. 89, no. 236, pg. 97826. December 9, 2024.
Empower your practice with cutting-edge thyroid ablation technology. The CRF Thyroid RFA System is the future of thyroid care — schedule your demo today!
The CRF radiofrequency ablation system of Cambridge Interventional LLC (“Cambridge”) is intended for use in percutaneous, laparoscopic and intraoperative coagulation and ablation of tissue.
Read the instructions for use (“IFU”) of all medical devices prior to use. Clinical results, costs, and financial/insurance coverage may vary and are not guaranteed. The information contained in the multimedia content that is contained herein or that is posted on the Cambridge Interventional website or that references or links to this text (“Content”) is for general informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment; standards of medical care or training; or the instructions, indications, and contraindications for use of Cambridge Interventional devices or any other medical devices. All information is provided in good faith, however Cambridge makes no representation or warranty of any kind, express or implied regarding the accuracy, applicability, fitness, or completeness of this information; of opinions expressed; of third-party publications referenced or summarized; or of third-party services presented. Always seek the advice of your physician about a medical condition. Never disregard professional medical advice, or delay in seeking it, because of something you have read or seen in this Content.
Reported adverse events or complications for RF ablation or coagulation procedures include, but are not limited to, the following (the long-term risks of RF ablations have not been established): abscess, ARDS (acute respiratory distress syndrome), arrhythmia, ascites, atrial fibrillation, bile duct injury, bile leakage, biliary fistula, biloma, bleeding, bone degeneration, bone fracture, bronchial occlusion, bronchopleural fistula, burn, cardiac arrhythmia, cardiac ischemia, chest tube, coughing, death, delayed hemorrhage into ablated tissue, device failure, device fracture in patient, diaphragm injury, diarrhea, edema, electric shock, emphysema, fever, fistula, hematoma, hematuria, hemoglobinuria, hemoptysis, hemorrhage, hemothorax, hoarseness, hypertension, hyperthyroidism, hypoesthesia, hypotension, hypothyroidism, infection, kidney atrophy, liver failure, liver insufficiency, multiple sclerosis exacerbation, muscle burn, muscle contracture, nausea/vomiting, nerve injury, neuropathy, nodule rupture, organ damage, pain, paresthesia, perforated colon, perforation, peritonitis, pes equinus injury, pleural effusion, pneumonia, pneumothorax, renal failure, skin burn, tumor recurrence, tumor seeding, urinary fistula, urinary incontinence, urinary retention, urine leakage, vasovagal reaction, vessel injury, vocal cord palsy, voice change, wound discharge. RF ablation procedures are not recommended for pregnant patients. Potential risks to the patient and/or fetus have not been established. General clinical residual risks for surgical procedures include anesthesia reaction, bleeding, blood clots, death, infection, organ injury, pain, and necessity for more invasive surgery, including open surgery, if complications occur.